Search Results

You are looking at 71 - 80 of 383 items for :

  • "bevacizumab" x
  • Refine by Access: All x
Clear All
Full access

Leonard Saltz

motivated and capable of accurately adhering to a complicated oral schedule. Bevacizumab The initial bevacizumab study, which evaluated the benefit of adding the drug to IFL (irinotecan, bolus fluorouracil, leucovorin), found a 4.7-month OS improvement

Full access

Jonathan W. Riess, Seema Nagpal, Joel W. Neal, and Heather A. Wakelee

histology. 2 Pemetrexed-containing first-line regimens are well tolerated by most patients and are associated with a much lower incidence of alopecia, neuropathy, and cytopenias than many other regimens. The additional benefit of adding bevacizumab to a

Full access

by the ORP. This feature highlights an NCCN study funded through the grant mechanism. TH-138: Phase II Randomized Trial of Carboplatin + Pemetrexed + Bevacizumab, With or Without Atezolizumab, in Patients With Stage IV Nonsquamous NSCLC Who Harbor a

Full access

Al B. Benson III, Alan P. Venook, Mahmoud M. Al-Hawary, Mustafa A. Arain, Yi-Jen Chen, Kristen K. Ciombor, Stacey Cohen, Harry S. Cooper, Dustin Deming, Linda Farkas, Ignacio Garrido-Laguna, Jean L. Grem, Andrew Gunn, J. Randolph Hecht, Sarah Hoffe, Joleen Hubbard, Steven Hunt, Kimberly L. Johung, Natalie Kirilcuk, Smitha Krishnamurthi, Wells A. Messersmith, Jeffrey Meyerhardt, Eric D. Miller, Mary F. Mulcahy, Steven Nurkin, Michael J. Overman, Aparna Parikh, Hitendra Patel, Katrina Pedersen, Leonard Saltz, Charles Schneider, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky-Himelfarb, Christopher G. Willett, Kristina M. Gregory, and Lisa A. Gurski

one regimen to be preferable over another as initial therapy for metastatic disease. The panel also does not indicate a preference for biologic agents used as part of initial therapy (ie, bevacizumab, cetuximab, panitumumab, none). Therapy Retreatment

Full access

Alan P. Venook

proved wrong was that a drug that works well in mCRC would also be effective in the adjuvant setting. In the NSABP and AVANT studies, 3 , 4 bevacizumab did not improve outcomes in patients with stage II or III disease, nor did cetuximab in the N0147

Full access

Diane Reidy and Leonard Saltz

R . Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naíve patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704 [abstract] . J

Full access

Elizabeth R. Plimack and Gary R. Hudes

endothelial growth factor (VEGF)-directed therapies (sorafenib, sunitinib, pazopanib, and bevacizumab) and mammalian target of rapamycin (mTOR) inhibitors (temsirolimus and everolimus). With such a large number of treatment options, selecting among them for a

Full access

Al B. Benson III

(Panitumumab Efficacy in Combination With mFOLFOX6 Against Bevacizumab plus mFOLFOX6 in Metastatic CRC Subjects With Wild-Type KRAS Tumors), were further assessed in secondary analyses to include extended RAS testing ( KRAS exons 2, 3, 4; NRAS exons 2, 3

Full access

Keith D. Eaton and Renato G. Martins

growth factor receptor (EGFR) to chemotherapy, 7 and the incorporation of other non-chemotherapy agents 8 all failed to improve survival and QOL. Recently, the addition of the anti–vascular endothelial growth factor (VEGF) antibody bevacizumab

Full access

Presented by: Joyce F. Liu

benefit from bevacizumab? Is testing for homologous recombination deficiency (HRD)/genomic instability appropriate? What is the role of maintenance therapy with PARP inhibitors? Of note, because the treatment of advanced ovarian cancer is complex and